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Abstract 
Over the past three decades the research on GABAB receptor biology and pharmacology in 
pain processing has been a fascinating experience. Norman Bowery’s fundamental 
discovery of the existence of the GABAB receptor has led the way to the definition of 
GABAB molecular mechanisms; patterns of receptor expression in the peripheral and central 
nervous system; GABAB modulatory functions within the pain pathways. We are now 
harnessing this acquired knowledge to develop innovative approaches to the therapeutic 
management of chronic pain through allosteric modulation of the GABAB.  Norman's legacy 
would be ultimately fulfilled by the development of novel analgesics that activate the GABAB 
receptor. 
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Introduction 
The GABAB receptor agonist (±)baclofen (β p-chlorophenyl-GABA)(Lioresal)  is the drug of 
choice for spasticity in multiple sclerosis and spinal injury and it is also used as analgesic for 
chronic pain associated with spinal cord injury and trigeminal neuralgia. Baclofen’s side 
effects such as sedation and motor impairment limit its systemic use, and intrathecal delivery 
is an alternative route of administration which also overcomes baclofen’s poor brain 
penetration (Bowery, 2006).  
In the nineties we knew that (-)baclofen was the stereo-selective ligand for the GABAB 
receptor which had been recognised by Norman Bowery as a receptor for GABA, which was 
different from the GABAA receptor (Hill and Bowery 1981).   GABAB receptor antagonists 
were also synthesised and made available by the CIBA-Geigy laboratories (Olpe et al., 
1990). However, it took a number of years for the gene encoding the metabotropic GABAB 
receptor to be cloned by Klemens Kaupmann and for GABAB1 and GABAB2 heterodimers to 
be identified as critical units for functional expression (Kaupmann et al., 1997; White et al., 
1998).  GABAB knock out mice were generated by the Novartis team 5 years after receptor 
cloning with the aim to establish the role of GABAB receptor in in vivo models of epilepsy, 
memory and pain (Schuler et al., 2001).  
In the early 90’s it became evident that the systemic administration of (±)baclofen resulted in 
analgesic and anti-hyperalgesic effects in experimental models of acute and chronic pain at 
doses which were significantly lower than those required for muscle-relaxation. Baclofen 
exerted antinociceptive effects when administered directly in the CNS by intrathecal and 
intracerebroventricular injections (Sawynok and LaBella, 1982; Wilson and Yaksh, 1978). 
Consistent with a central site of action for baclofen, GABAB receptor antagonists injected 
intrathecally were able to prevent the analgesic effect of systemic baclofen (Malcangio et al., 
1991). Indeed, autoradiography binding studies demonstrated that GABAB receptors in the 
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spinal cord were localised mainly in the superficial laminae of the dorsal horns where they 
were found on both primary afferent fibre terminals and intrinsic neurons (Malcangio et al., 
1993; Price et al., 1987; Price et al., 1984).  The expression of GABAB receptors in the 
dorsal horn showed plasticity and underwent up- or down-regulation after systemic treatment 
with receptor antagonists or baclofen (Malcangio et al., 1993). GABAB receptor plasticity 
explained the tolerance to the analgesic effect of baclofen that developed after prolonged 
treatments and it limited the chronic use of the drug (Malcangio et al., 1993).  At the same 
time it was clear that baclofen-induced analgesia was effected through a novel pathway, 
independent from the opioid system as it was not reversed by naloxone. Equally, the 
pathway was distinct from GABAA receptor activation as the effect of baclofen was not 
blocked by bicuculline. 
GABAB receptors 
The cloning of the two GABAB receptor subunits demonstrated that GABAB receptors are 
metabotropic members of the seven transmembrane G-Protein coupled receptors 
superfamily, which belong to the same class as metabotropic glutamate receptors (mGluRs), 
calcium-sensing receptors and receptors for umani and sweet taste. GABAB receptor 
activation is associated with opening of inwardly rectifying potassium channels, inhibition of 
calcium channels and activation of adenylyl cyclase. GABAB receptors have a heterodimeric 
structure and complete receptor function requires the assembly of GABAB1 and GABAB2 
subunits, which are linked by protein/protein interactions between their intracellular C-
terminal domains. The GABA binding site is located on the extracellular domain of the 
GABAB1 subunit, whilst the GABAB2 subunit interacts with the G proteins and is essential for 
functional expression of the receptor.  GABAB receptor subunits are found both centrally and 
peripherally including the thalamus, brain stem nuclei and spinal cord.  
Acute and chronic pain 
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Pain is a subjective experience associated with actual or potential tissue damage. It is a 
sensation in a part of our body that is also unpleasant, and therefore an emotional 
experience. Pain can be acute or chronic: acute pain is a warning system essential for 
survival and well-being whilst chronic pain does not serve any useful protective mechanism 
for the organism, outlasts the noxious stimulus and is poorly controlled by current analgesics 
(Woolf, 2010). The pain experience is mediated by specialised primary afferent fibres, 
namely the nociceptors, which detect noxious stimuli in the periphery and transmit electrical 
impulses centrally to the spinal cord on their way to the brain where pain is perceived. 
Interestingly, the underlying organization and strengthening of nociceptive circuitry in the 
dorsal horn in adulthood can be altered by sensory inputs in early life (Fitzgerald, 2005) and 
during early development GABA can induce depolarization due to reduced neuronal ability to 
extrude chloride ions (Baccei, 2016). 
There are profound differences between acute and chronic pain when dramatic changes 
occur in peripheral nociceptors and central nociceptive pathways and the pain system is 
sensitised thereby leading to exaggerated responses to noxious stimuli (hyperalgesia) and 
responses to non-noxious stimuli (allodynia) (Sandkühler, 2009). Tissue injury results in 
inflammatory pain in diseases such as rheumatoid arthritis (Üçeyler et al., 2009). 
Neuropathic pain results from lesions to the peripheral nervous system caused by 
mechanical trauma, metabolic diseases such as diabetes or neurotoxic chemicals such as 
chemotherapeutic agents. In chronic pain states the increased nociceptive input from the 
periphery triggers the physiological plasticity and long lasting transcriptional and post-
translational changes in the CNS defined as central sensitization (Kuner, 2010). Glial cells in 
the spinal cord, such as microglia and astrocytes, also contribute to central sensitization 
(Malcangio, 2016; McMahon and Malcangio, 2009) and cortical and sub-cortical structures 
modulate pain (Eippert et al., 2009).  Under neuropathic pain conditions, loss of function of 
inhibitory neurons at the level of the spinal cord contributes to the increased excitation and in 
chronic inflammatory pain GABAergic inhibition is decreased in the spinal cord (Takazawa et 
al., 2017; Zeilhofer et al., 2012).  
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GABA and GABAB receptors in pain  
GABA is expressed by inhibitory interneurons in the laminae I-III of the dorsal horns which 
constitute a different neuronal population from excitatory interneurons expressing glutamate 
(Polgar et al., 2003; Polgár et al., 2013; Zeilhofer et al., 2012). GABAergic islet cells that 
contain parvalbumin are innervated by myelinated primary afferent fibres which receive 
axoaxonic synapses from GABAergic cells. Such GABA-mediated pre-synaptic inhibition is 
likely to regulate myelinated fibres activity following non-noxious mechanical stimulation in 
the periphery. GABAergic interneurons which also contain neuropeptide Y innervate 
projection neurons expressing NK1 receptor for Substance P (SP) and those which also 
contain nNOS innervate giant cells in lamina I. As NK1 projection neurons are innervated by 
the nociceptive C fibres, these GABAergic synapses are likely to regulate activity in 
response to nociceptive inputs from the periphery.  
GABA modulates nociceptive transmission at the level of the dorsal horn through activation 
of both GABAA and GABAB receptors that are located on primary afferent terminals as well 
as dorsal horn neurones, including lamina I spinothalamic projection neurons (Calver et al., 
2000).  
In the spinal cord GABAB receptors regulate the activity of both peptidergic primary afferent 
terminals and dorsal horn neurons. Indeed, baclofen application to the dorsal horns isolated 
in vitro inhibits the release of  SP evoked by activation of primary afferent fibres (Malcangio 
and Bowery, 1993) as well as the internalization of the NK1 receptors on projection neurons 
(Marvizon et al., 1999). Baclofen inhibits C fibre-evoked activity of convergent/multireceptive 
neurons in anaesthetised rats (Dickenson et al., 1985). Furthermore, baclofen inhibits c-fos 
expression in dorsal horn neurons after exogenous SP application (Riley et al., 2001). 
Notably, the effect of baclofen on NK1 receptor internalization are significant after intrathecal 
rather than systemic administration which results, as discussed above, in a predominant 
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muscle relaxant effect (Riley et al., 2001). GABAB receptors are localized on the terminals of 
peptidergic primary afferents fibers (Malcangio et al., 1993; Price et al., 1984). At 
presynaptic sites the GABAB receptor activation leads to inhibition of high voltage-gated Ca2+ 
channel activity and inhibits glutamate as well as SP and CGRP release (Bowery, 2006; 
Malcangio and Bowery 1995; Malcangio and Bowery, 1993; Marvizon et al., 1999). The 
decrease of dorsal horn neuron excitability (Kangrga et al., 1991), and the regulation of 
intrinsic neuronal properties (Derjean et al., 2003) suggest an additional postsynaptic site for 
the baclofen action on pain.  
As the effects of baclofen on primary afferent activity are not reproduced by GABAA receptor 
agonists like muscimol and isoguvacine, this ionotropic receptor may play minimal role in the 
modulation of primary afferent activity. However, it is important to note that post-synaptic 
GABAA receptors remain critical for mediating GABA-induced analgesia and indeed some 
benzodiazepine that are GABA  mimetic drugs at the GABAA receptors exert analgesic 
effects. In the case of systemic diazepam, the site of action appears to be the spinal cord 
where GABAA receptor subunits α2 and α3 are responsible for analgesic effects (Knabl et 
al., 2008; Knabl et al., 2009). 
GABAB1 knock out mice which lack GABA binding sites and functional GABAB receptors 
display reduced sensitivity to hot and mechanical nociceptive stimulation and confirm the 
existence of a GABAB-mediated tone of pain and the possibility that GABAB modulators 
would act synergistically with endogenous GABA.  
GABAB and inflammatory pain 
Under inflammatory pain conditions such as in rat models of monoarthritic inflammatory pain, 
GABA is up-regulated in dorsal horn superficial laminae (Castro-Lopes et al., 1992) and 
down-regulated in the ventrobasal thalamus (Zhang et al., 2017) and animals are less 
sensitive to the analgesic effect of systemic baclofen (Castro et al., 1999; Malcangio and 
Bowery, 1994). Recent evidence indicates that GABA-mediated inhibitory activity is 
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decreased in the dorsal horn after peripheral inflammation and contributes to reduced 
inhibition under persistent pain conditions (Takazawa et al., 2017).  
Whilst selective deletion of peripheral GABAB1 receptor subunit in sensory neurons indicated  
no major role in inflammatory pain (Gangadharan et al., 2009), both GABAB receptor 
activation in the spinal cord and ventrolateral thalamus contribute to the anti-nociceptive 
effect of baclofen (Buritova et al., 1996; Potes et al., 2006).  Recently, GABA expression has 
been identified in sensory neurons which also express the GABAB1 receptor subunit in close 
juxtaposition with TRPV1 receptors. A fascinating possibility is that GABA via activation of 
GABAB1 autoreceptor can attenuate sensitization of TRPV1 receptor in nociceptors (Hanack 
et al., 2015).  A strategy which has yielded significant success evolved around the 
development of positive allosteric modulators, or PAMs. PAMs provide an opportunity for 
selectivity as these molecules become operative only in the presence of the endogenous 
agonist, when they display the positive enhancing effect on receptor activation. The rationale 
herein would be to positive modulate GABAB receptor activity only at synapses where GABA 
is released. Of importance, PAMs can enhance activity of orthosteric agonists like baclofen. 
Congruently, ADX71441, a compound developed very recently, showed limited muscle 
relaxant activity but significant anti-nociceptive activity in the inflammatory phase of the 
monoiodoacetate model of osteoarthritis (Kalinichev et al., 2017).  
GABAB and neuropathic pain 
In neuropathic pain conditions, GABAergic inhibitory control at the level of the spinal cord is 
significantly reduced and contributes to increased excitation and central sensitization of pain 
transmission. Such loss of inhibition is the result of several possible mechanisms including 
death of inhibitory neurons (Castro-Lopes et al., 1992; Ibuki et al., 1996; Moore et al., 2002; 
Yowtak et al., 2013) but see (Polgár and Todd, 2008), diminished neuronal activity and 
decreased release of GABA (Leitner et al., 2013; Lever et al., 2003; Schoffnegger et al., 
2006). Despite the reduced endogenous GABAergic tone, baclofen exerts anti-nociceptive 
effects in neuropathic animals and intraspinal transplantation of cortical precursors of 
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GABAergic interneurons from the medial ganglionic eminence (MGE approach) which can 
release GABA, can reverse neuropathic allodynia (Bráz et al., 2015). Notably, MGE 
approach is effective in chemotherapy-induced pain models in which GABA levels are not 
altered (Bráz et al., 2015).  In addition, still in models of chemotherapy-induced neuropathy,  
significant up-regulation of GABAB receptors in sensory neurons mediates the sustained 
analgesic effect of the opioid oxycodone (Thibault et al., 2014).  
Neuropathic animals display increased sensitivity to the anti-nociceptive effect of baclofen 
and whilst the number and affinity of GABAB binding sites in the dorsal horn are not altered 
(Smith et al.,1994; (Zemoura et al., 2016), GABAB receptors subunits (B1 and B2) are both 
down-regulated in sensory neurons after nerve injury (Engle et al., 2012) and GABAB1 down-
regulation in nociceptive neurons is a  likely contributor to reduced GABA-mediated inhibition 
of nociceptive input in the dorsal horn.  Allosteric modulators of GABAB receptors such as 
rac-BHFF, have not shown efficacy in neuropathic mice and suggest a limited role for that 
GABAB-mediated mechanisms under this condition (Zemoura et al., 2016) 
On a more positive note, baclofen has shown anti-hyperlagesic effects in cancer induced 
bone pain (CIBP) which is poorly managed with currently available analgesics including 
opioids. GABAB receptors undergo down regulation in the dorsal horn of CIBP rats where 
they are expressed mainly by neurons. Interestingly, prolonged treatment with baclofen 
restored receptor expression (Zhou et al., 2017). Whether GABAB allosteric modulators are 
effective analgesic in CIBP remains to be explored.  
Conclusion 
In conclusion, over the past three decades the research on GABA biology and pharmacology 
has been a fascinating voyage. From the intuition of Norman Bowery on the existence of a 
second receptor for GABA to the definition of GABAB molecular mechanisms, patterns of 
expression and potent modulatory functions within the CNS, we are now harnessing this 
science for innovative approaches to the therapeutic management of pain. In this review I 
have brought together this knowledge which has stemmed from Bowery’s discovery with the 
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excitement and awareness that his legacy would be fulfilled by the development of novel 
analgesics able to activate the GABAB receptor.   
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Over the past three decades the research on GABAB receptor biology and pharmacology in 
pain processing has been a fascinating experience. Norman Bowery’s fundamental 
discovery of the existence of the GABAB receptor remains essential for the discovery of 
novel analgesics that activate the GABAB receptor. 
 
